07/05/2021

IP waiver for COVID-19 vaccines is a misguided and ineffective response to a shared global challenge

2021_05_H_PR_Waiver of Intellectual Property Rights for COVID-19 Vaccines – EuropaBio’s Position
25/03/2021

EuropaBio Statement – Vaccine production scale up: International collaboration remains the key

EuropaBio Statement – Vaccine production scale up: International collaboration remains the key.
20/05/2020

The impact of COVID-19 on patients with chronic or life-threatening conditions

Read our latest blog on the impact of the pandemic on patients with chronic diseases and rare conditions around the globe.
30/04/2020

How soon can we respond to COVID-19?

The development of a vaccine or an antiviral treatment is a long and complex process. So why are we hearing that a vaccine against COVID-19 may be ready in a year from now, or even sooner?
30/04/2020

EuropaBio reply letter to European Patients’ Forum’s call on COVID-19

EuropaBio reply letter to EPF's call on COVID-19.
30/04/2020

CRISPR and Coronavirus

A recent interview with Prof. Jennifer Doudna, a co-discoverer of the CRISPR-Cas9 system for genome editing, highlights potential applications of the technology to COVID-19.
30/04/2020

Clinical Trials and Coronavirus

Check out the latest news on coronavirus clinical trials.
10/04/2020

European Industry trade and supply chain needs to respond to Covid-19 – Joint Letter to the EU Trade Ministers

European Industry trade and supply chain needs to respond to Covid-19 - Joint Letter to the EU Trade Ministers.
30/03/2020

Biotechnology spearheads the fight against COVID-19

Learn how biotechnology can contribute towards fighting COVID-19 in our latest blog post.
Become a member